RxDoctor Payments Data

Michael Musgrove, MD

Psychiatry · Round Rock, TXNPI 1033166368

Payments from drug & device makers

$19,566in general payments, 2019–2025

Across 1,077 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$3K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Neurocrine Biosciences, Inc.$2K
  • Lundbeck LLC$2K
  • AbbVie$1K
  • Alkermes, Inc.$1K
  • plus $9K from 33 others

What the payments were for

  • Consulting fees$2201%
  • Speaking & faculty fees$4402%
  • Food & beverage$18,86396%
  • Education$430%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,566 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$39,298
Medicare patients
101
Services billed
306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine15$103,470
CaplytaLumateperone Tosylate12$18,043
Lisdexamfetamine Dimesylate44$11,019
AdderallDextroamphetamine/Amphetamine12$5,828
BelsomraSuvorexant11$4,949
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine65$3,858
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine85$2,912
Desvenlafaxine Succinate ErDesvenlafaxine Succinate49$2,141
Bupropion XlBupropion Hcl74$2,131
Methylphenidate ErMethylphenidate Hcl30$1,983
Duloxetine Hcl71$1,877
Atomoxetine Hcl15$1,591
Armodafinil24$1,413
Escitalopram Oxalate65$1,329
Lamotrigine72$1,216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$877$103,47015 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,609$18,04312 claims
Takeda Pharmaceuticals U.S.A., Inc.Adderall$877$5,82812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →